EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study

Saana Virtanen, Heidi Pihlman, Maria Silvoniemi, Pia Vihinen iD, Panu Jaakkola iD, Kalle E Mattila iD

Cancers · 07.02.2024 · 16 (4) · 709

DOI: 10.3390/cancers16040709 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancers, online erschienen am 07.02.2024. Verfasst von Saana Virtanen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapy, Fican West Cancer Centre, Turku University Hospital, University of Turku, 20521 Turku, Finland. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) have improved survival in several cancer types. Still, most patients develop disease progression during or after treatment. We evaluated the reasons for treatment discontinuation and their effect on treatment outcomes in adult patients with advanced cancer with ICI in the first or later treatment lines in Southwest Finland between 1 January 2015 and 31 December 2021. Baseline characteristics and treatment outcomes were retrospectively obtained from the electronic medical records. There were 317 patients with 15 different cancer types, most commonly non-small cell lung cancer, melanoma, and kidney cancer, treated with ICI outside clinical trials. During follow-up, 94% of the patients had discontinued treatment. A total of 62% was due to disease progression, 17% due to immune-related adverse events (irAEs), 12% after achieving disease control or radiological response, and 9% due to poor performance status. The median progression-free survival (mPFS) was 5.4 months and the median overall survival (mOS) was 20.3 months in the whole cohort. Longer mPFS and mOS were observed in patients who discontinued ICI due to irAEs (24.3 and 49.2 months) and after disease control (49.7 months and not reached). In total, 46% of the patients who discontinued ICI after irAEs or disease control remained alive and progression-free during follow-up.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmune-related adverse eventsimmunotherapyoverall survivalprogression-free survivalreal-world evidencetreatment discontinuation

Autor:innen und Institutionen

  • Department of Oncology and Radiotherapy, Fican West Cancer Centre, Turku University Hospital, University of Turku, 20521 Turku, Finland.
  • Department of Respiratory Medicine, Turku University Hospital, University of Turku, 20521 Turku, Finland.
  • InFLAMES Research Flagship Center, University of Turku, 20521 Turku, Finland.

ORCID-Profile: Pia Vihinen, Panu Jaakkola, Kalle E Mattila

Zitieren

APA

Virtanen, S., Pihlman, H., Silvoniemi, M., Vihinen, P., Jaakkola, P., & Mattila, K. E. (2024). Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study. Cancers, 16(4), 709. https://doi.org/10.3390/cancers16040709

Vancouver

Virtanen S, Pihlman H, Silvoniemi M, Vihinen P, Jaakkola P, Mattila KE. Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study. Cancers. 2024;16(4):709. doi:10.3390/cancers16040709

BibTeX
@article{Virtanen2024,
  author = {Virtanen, Saana and Pihlman, Heidi and Silvoniemi, Maria and Vihinen, Pia and Jaakkola, Panu and Mattila, Kalle E},
  title = {Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {709},
  doi = {10.3390/cancers16040709}
}
Kostenlos starten →